Registry for Pulmonary Hypertension Due to Left Heart Disease in China

Pulmonary Hypertension Due to Left Heart Disease Clinical Trial

Official title:

National, Prospective, Multicenter,Observational Registry Study on Pulmonary Hypertension Due to Left Heart Disease in China

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02164526
• Other study ID #: CRPHDLHD
• Status: Recruiting
• Phase: N/A
• First received: June 4, 2014
• Last updated: June 13, 2017
• Start date: January 2013
• Est. completion date: December 2018

Study information

• Verified date: June 2017
• Source: Chinese Academy of Medical Sciences, Fuwai Hospital
• Contact: Jianguo He, MD
• Phone: 861088398826
• Email: hejianguofw[@]gmail.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Left heart disease is the main cause of pulmonary hypertension. With the advent of the aging society, chronic heart failure has become a global public health problem. Therefore the prevalence of pulmonary hypertension due to the left heart disease is increasing. However, there is no research on the prevalence of pulmonary hypertension due to the left heart disease in China. Therefore, the aim of the present study was to describe real-world outcome of Chinese patients with pulmonary hypertension due to the left heart disease and identify factors that may predict outcome. Our study will profile the demographics, clinical course, treatments, and outcomes of pulmonary hypertension due to the left heart disease in China.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 520
• Est. completion date: December 2018
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Pulmonary Hypertension due to left heart disease

Exclusion Criteria:

• Other forms of Pulmonary Hypertension

• Heart failure due to valvular heart disease

• Hypertrophic obstructive cardiomyopathy

• Right ventricular outflow tract stenosis

• Pericardial disease

• Patients with chronic lung disease

Related Conditions & MeSH terms

• Heart Diseases
• Hypertension
• Hypertension, Pulmonary
• Pulmonary Hypertension Due to Left Heart Disease

Intervention

Other:
• Routine therapy
Routine therapy

Locations

Country	Name	City	State
China	State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences	Beijing	Beijing
China	State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese Academy of Medical Sciences, Fuwai Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All cause death		up to 5 years